Table 1.
Patient baseline demographic and clinical characteristics
| Characteristics | Control group (n = 74) | Pirfenidone final group (n = 122) | Pirfenidone pre-selection group (n = 281) |
|---|---|---|---|
| Age (years) | 59 ± 9 | 64 ± 12 | 62 ± 12 |
| Female [n (%)] | 54 (73%) | 71 (58%) | 138 (49%) |
| Cirrhosis cause | |||
| HCV [n (%)] | 30 (40.5%) | 27 (22%) | 71 (25.3%) |
| HCB [n (%)] | 0 | 0 | 5 (1.8%) |
| NAFLD [n (%)] | 27 (36.5%) | 53 (43%) | 113 (40.2%) |
| ALD [n (%)] | 8 (11%) | 21 (17%) | 45 (16.1%) |
| Autoimmune [n (%)] | 9 (12%) | 21 (17%) | 47 (16.7%) |
| Fibrosis METAVIR score | |||
| F3 [n (%)] | 3 (4%) | 32 (26%) | 62 (22%) |
| F4 [n (%)] | 71 (96%) | 90 (74%) | 219 (78%) |
| Child–Pugh score | |||
| A [n (%)] | 68 (96%) | 65 (72.2%) | 208 (74%) |
| B [n (%)] | 3 (4%) | 23 (25.6%) | 65 (23%) |
| C [n (%)] | 0 | 2(2.2%) | 8 (3%) |
| Cirrhosis stage | |||
| 1 [n (%)] | 39 (54.9%) | 43 (47.7%) | 57 (26.4%) |
| 2 [n (%)] | 29 (40.8%) | 30 (33.3%) | 110 (50.9%) |
| 3 [n (%)] | 3 (4.3%) | 12 (13.3%) | 35 (16.2%) |
| 4 [n (%)] | 0 | 5 (5.7%) | 14 (6.5%) |
| MELD score | |||
| ≤ 9 | 45 (63%) | 27 (30%) | 130 (46%) |
| 10–19 | 24 (34%) | 63 (70%) | 143 (51%) |
| ≥ a 20 | 2 (3%) | 0 | 8 (3%) |